Algert Global LLC Buys New Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Algert Global LLC purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 45,015 shares of the life sciences company’s stock, valued at approximately $1,312,000. Algert Global LLC owned 0.06% of Integra LifeSciences at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IART. Capital Research Global Investors raised its holdings in shares of Integra LifeSciences by 37.7% in the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares in the last quarter. Cooke & Bieler LP increased its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after buying an additional 388,710 shares during the last quarter. Champlain Investment Partners LLC raised its stake in Integra LifeSciences by 10.3% in the first quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock valued at $95,289,000 after buying an additional 252,015 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after acquiring an additional 12,766 shares in the last quarter. Finally, Madison Avenue Partners LP increased its holdings in shares of Integra LifeSciences by 8.0% in the 4th quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock valued at $45,386,000 after acquiring an additional 77,489 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IART shares. Truist Financial cut their price objective on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. BTIG Research reduced their price target on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research report on Wednesday, August 28th. JMP Securities cut their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Morgan Stanley raised their price target on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Finally, Citigroup decreased their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $28.13.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $16.95 on Friday. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 33.90, a price-to-earnings-growth ratio of 0.60 and a beta of 1.09. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The firm’s fifty day moving average price is $20.50 and its 200 day moving average price is $26.83.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. During the same period in the prior year, the company posted $0.71 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.